Multidisciplinary Conference of Benign Esophageal Disease: Case 1

Listen to the panel discussion on Case 1 of 5 of the Multidisciplinary Tumour Board, moderated by Mark Smithers and Nicholas Shaheen. The international panel of experts included: Gastroenterology panelists:  Peter Kahrilas, Sachin Wani, Vani Konda, Felice Schnoll-Sussman Surgery panelists:  John Hunter, Sheraz Markar, Donald Low, John Lipham This presentation…

Continue reading

Endoscopic Salvage after CRT for Esophageal Cancer – Seiichiro Abe

Listen to Dr. Seiichiro Abe present during the Esophageal Cancer and Pathologic Response: Is Esophagectomy Always Needed? Session, held during the 2025 ISDE World Congress in Brisbane Australia from September 18-20, 2025. Watch all presentations in this session including: Pathologic Response with Perioperative Chemotherapy Versus CRT: Are They Both Equivalent…

Continue reading

Surgery After Wait and See in Patients After Def CRTx – Wayne Hofstetter

Listen to Dr. Wayne Hofstetter present during the Esophageal Cancer and Pathologic Response: Is Esophagectomy Always Needed? Session, held during the 2025 ISDE World Congress in Brisbane Australia from September 18-20, 2025. Watch all presentations in this session including: Pathologic Response with Perioperative Chemotherapy Versus CRT: Are They Both Equivalent…

Continue reading

Definitive CRTx – Does Proton Therapy Has a Role – Karin Haustermans

Listen to Dr. Karin Haustermans present during the Esophageal Cancer and Pathologic Response: Is Esophagectomy Always Needed? Session, held during the 2025 ISDE World Congress in Brisbane Australia from September 18-20, 2025. Watch all presentations in this session including: Pathologic Response with Perioperative Chemotherapy Versus CRT: Are They Both Equivalent…

Continue reading

Our Surgical Technique of Combined Resection with Aortic Adventitia Using Da Vinci Xi for Esophageal Cancer Invading Descending Aorta – Tomoki Makino

A 65-year-old male with lower esophageal adenocarcinoma classified as cT4b (invasion of the descending aorta) N2M0, cStageIVa, underwent six courses of chemotherapy (5FU+CDDP) combined with PD-1 antibody therapy at a previous institution. While the primary tumor showed a partial response (PR) according to RECIST criteria, residual tumor was observed on…

Continue reading